@ Gabrielle | SEBIO

Academic Patent Licensing Helps Drive the U.S. Economy

Posted by on Jun 23, 2017 in Newsroom | 0 comments

Just as some politicians are increasing their calls for Washington micromanagement of  the Bayh-Dole law (which allows universities and federal laboratories to license federally supported inventions for commercial development) a new study shows how impressively the current decentralized, market driven system is performing. “Thanks to the enduring effectiveness of the Bayh-Dole Act, American research universities, along with industry partners, are turning federally-funded basic research into new and valuable products that save and improve lives. The commercialization of university-based...

Read More

Registration OPEN for SEBIO Forum

Posted by on Jun 22, 2017 in Newsroom | 0 comments

Early Registration is now open for the 19th Annual  SEBIO Investor and Partnering Forum.  Come join us in Pinehurst!!  

Read More

World-leading Seqirus flu vax factory in Holly Springs hits another milestone

Posted by on Jun 22, 2017 in Newsroom | 0 comments

HOLLY SPRINGS, N.C. – The billion-dollar cell culture Seqirus vaccine factory in Holly Springs has hit yet another milestone. The 550 highly skilled workers at the sprawling factory southeast of Raleigh successfully produced the world’s first cell-based influenza vaccine at commercial scale using a candidate vaccine virus (CVV) that has been isolated and grown in cells, rather than in eggs. CVVs are prepared by the World Health Organization (WHO) Global Influenza Surveillance and Response System (GISRS) and associated laboratories, and are used by manufacturers to develop and produce...

Read More

Apply to Present at the SEBIO Investor & Partnering Forum

Posted by on Jun 19, 2017 in Uncategorized | 0 comments

Companies applying to present at the SEBIO Investor & Partnering Forum are classified as either Early/Stage Companies or Main/Stage Companies. The Selection Criteria used to judge the candidates will be applied to both groups, recognizing the likely distinctions in factors such as completeness of the management team, funding history and stage of technology development. 

Read More

Vigilant Biosciences Announces Grant Award from National Institutes of Health

Posted by on Jun 15, 2017 in Newsroom | 0 comments

FORT LAUDERDALE, FL. – Vigilant Biosciences, Inc., a leading innovator and developer of solutions that aid in the early detection and intervention of cancer, today announced the that it has received an award as part of a multi-million dollar grant from the National Institutes of Health to fund research in support of a novel point of care test to improve early identification of oral and oropharyngeal cancer. The five-year study will enroll 300 mouth and throat cancer patients and control subjects in a multi-institutional setting. Institutions participating in the study include UC San...

Read More